The 4th Nasal Formulation & Delivery Summit is a specialist meeting focused on the formulation, delivery, and regulatory challenges of intranasal therapeutics.
This guide covers device innovation, excipient selection, bioavailability considerations, and routes to clinical and commercial success.
Key themes include:
- Nasal formulation design and excipients
- Device development and optimization
- Bioavailability and absorption challenges
- Regulatory and clinical pathways
About Hanson Wade Group - 4th Nasal Formulation & Delivery Summit
Secure Drug & Device Compatibility & Commercial Viability to Advance Best in Class Intranasal Treatment for CNS, Emergency-Use, Neurological & Infectious Diseases for Unparalleled Patient Efficacy
The 4th Nasal Formulation & Delivery Summit is uniting formulation, delivery, and product development leaders from across pharma and biotech to advance the development of safe, effective, and commercially viable intranasal therapies. As intranasal delivery gains validation across systemic, CNS, and emergency-use indications, the pressure to optimize formulations, align drug–device strategies, and generate predictive preclinical and clinical data has never been greater.
In an era of accelerating approvals, expanding modalities, and heightened regulatory scrutiny, teams must move beyond proof-of-concept to ensure intranasal programs are scalable, translatable, and fit for commercialization. Success now depends on solving formulation and delivery challenges early, while designing development strategies that withstand clinical, regulatory, and manufacturing demands.
This year, join 70+ experts from Eli Lilly, Bayer, Neurelis, Virpax Pharmaceuticals, Belhaven Biopharma, and more to explore real-world preclinical and clinical data, compare liquid and powder nasal approaches, and align on best practices for systemic and nose-to-brain delivery. Don’t miss the only industry-led meeting dedicated exclusively to end-to-end intranasal formulation, delivery, and commercialization.
Download the Event Guide
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.